FLT1 and colorectal carcinoma: REG involved in our study has been authorized by the FDA for the therapy of CRC, GIST, and HCC through targeting tumor cell growth and vasculature formation by potently inhibiting RTK VEGFR1, 2, and 3, TIE2, and PDGFR-b [32].